Cabotegravir - ViiV Healthcare

Drug Profile

Cabotegravir - ViiV Healthcare

Alternative Names: 1265744; 744 LA Injection; 744 Tablet; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAP

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
  • Class Antiretrovirals; Fluorobenzenes; Oxazoles; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 21 Aug 2018 ViiV Healthcare in collaboration with Janssen plans a phase II trial for HIV infections in USA , (NCT03639311)
  • 13 Jul 2018 National Institute of Allergy and Infectious Diseases completes a phase II trial for HIV infections (Prevention) in USA, South Africa, Brazil, Malawi (PO, IM) (NCT02178800)
  • 13 Jul 2018 National Institute of Allergy and Infectious Diseases completes a phase II trial for HIV infections in USA, South Africa, Brazil, Malawi (PO, IM) (NCT02178800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top